hUC-MSC_Prolonged
Phase 2Small molecule
hUC-MSC_Prolonged is one of 11 small molecule programs targeting Acute-on-Chronic Liver Failure. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Acute-on-Chronic Liver Failure
#DrugCompanyPhaseTrials
1Glypressin
MMallinckrodt
Approved
Vemlidy
GileadPreclinical
Proamatine
TakedaPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Coreg
Akero TherapeuticsPreclinical
Tenofovir (TFV) IVR
GileadPreclinical
Plasma Exchange
SanofiPreclinical
hUC-MSC_Prolonged
BBeijing 302 Hospital
Phase 2
Albumin
LLaboratoire français de Fractionnement et de Biotechnologies
Preclinical
G-CSF
AArog Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute-on-Chronic Liver Failure1 trial
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
Recruiting·—·Phase 1/2·NCT05985863·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hUC-MSC_Prolonged. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeijing 302 Hospital